Reported about 11 hours ago
Insilico Medicine Inc., an AI-driven drug discovery startup with a valuation exceeding $1 billion, is contemplating an IPO in Hong Kong after a successful funding round led by Value Partners Group. The company aims to enhance its AI platform and expedite clinical trials for its lead drug candidate, Rentosertib, although it has previously let two IPO applications lapse. Insilico plans to leverage its new capital for further development in the competitive field of AI-assisted drug discovery.
Source: YAHOO